MAGED1 and pulmonary arterial hypertension: The researchers found that MAGED1 regulates PAH pathogenesis by directly targeting m6A. YTHDF1 promoted PASMC proliferation and the development of PAH by increasing MAGED1 translation, and MAGED1 knockdown reduced hypoxia-induced proliferation of PASMCs by downregulating proliferating cell nuclear antigen (PCNA) (Hu et al., 2021).